Phase 3 results posted: A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer — UroGen Pharma Ltd.
Why now
Thesis: Bladder cancer trial results inform UroGen's pipeline
Catalyst to watch: Regulatory submission or approval decision
Main risk: Results may not support approval
Why it matters
Phase 3 results posting for a bladder cancer therapy informs regulatory prospects for the sponsor.
Details
Sponsor: UroGen Pharma Ltd.; Status: Active Not Recruiting; Conditions: Bladder Cancer, Urothelial Carcinoma, Urothelial Carcinoma Bladder; Interventions: UGN-103; Enrollment: 99 (actual); First posted: 2024-03-26; Results posted: 2026-09-28; NCT: NCT06331299
Related assets & topics
HealthcareSources
- clinicaltrials · 2026-09-28 12:00 UTC